GURU.Markets stock price, segment price, and overall market index valuation
The company's share price SGMT
The shares of Sagimet, a biotech company focused on treating nonalcoholic steatohepatitis (NASH), reflect the enormous potential of this market. The price chart is a story of investor hopes for the success of its drug in clinical trials, compared to numerous competitors.
Share prices of companies in the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis. We've categorized it as a Pharmaceutical: Metabolism company. The chart below shows how investors value companies in this competitive space.
Broad Market Index - GURU.Markets
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat metabolic diseases such as non-alcoholic steatohepatitis. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
SGMT - Daily change in the company's share price SGMT
For Sagimet, a biopharmaceutical company, change_co is a measure of reaction to clinical and regulatory news. Daily fluctuations reflect the volatility associated with drug development. This metric is a key element in analyzing young biotech companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Sagimet Biosciences Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the dynamics of SGMT, which focuses on liver disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as NASH. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization SGMT
Sagimet Biosciences' year-end performance is a story about the development of a drug for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease. Its market capitalization over the next 12 months depends entirely on the results of clinical trials. Success in this area could make it a leader in a multi-billion-dollar market where no approved drugs exist.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Sagimet Biosciences Inc. is a late-stage biotech developing drugs for the treatment of metabolic steatohepatitis (MASH). Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its drugs in this highly competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sagimet Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization SGMT
The value of Sagimet, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of its clinical trials for its drug for the treatment of metabolic steatohepatitis (MASH), the success of which determines its future.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Sagimet Biosciences is a biotech company developing drugs for the treatment of metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This pharmaceutical segment is attracting significant attention. The industry's dynamics reflect investors' hopes for the first effective treatment, and Sagimet is one of the contenders in this intense race.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing oral therapies for the treatment of non-alcoholic steatohepatitis (NASH) and oncology. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how scientific data and trial progress have impacted its stock.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization SGMT
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing drugs for the treatment of liver diseases such as NASH (steatohepatitis). Its weekly stock price is volatile and depends on news of clinical trial results.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Sagimet Biosciences develops drugs to treat metabolic diseases such as fatty liver disease. This represents a huge potential market, but the path to it requires expensive research. The chart below shows how development news impacts the company's stock, causing it to move independently of the overall pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Sagimet is a clinical-stage biotech. Its shares are driven by news about trials, not by macroeconomics. The chart clearly demonstrates how the company's performance is detached from the stock market and is determined by its own scientific successes or failures.
Market capitalization of the company, segment and market as a whole
SGMT - Market capitalization of the company SGMT
Sagimet Biosciences' market capitalization reflects investor expectations for its lead drug, MASH, for the treatment of metabolic liver disease. As a clinical-stage biotech, its price is highly volatile and driven by trial results. It's a high-risk bet on success in a highly competitive field.
SGMT - Share of the company's market capitalization SGMT within the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotech developing drugs to treat metabolic diseases such as steatohepatitis (NASH). Its market share reflects the potential of its lead candidate. This represents a bet on success in treating this very common but complex disease.
Market capitalization of the market segment - Pharma metabolism
The chart below shows the overall value of the biotech sector. Sagimet Biosciences is a company focused on treating metabolic diseases such as NASH. The potential of this market is enormous. Sagimet's performance, compared to this market, tells a story of hope that its unique approach to blocking fat synthesis in the liver will lead to the creation of the first effective drug.
Market capitalization of all companies included in a broad market index - GURU.Markets
Sagimet Biosciences develops drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Its market capitalization reflects the development of therapies for this common condition. The chart below shows the weighting of biotech companies in this field.
Book value capitalization of the company, segment and market as a whole
SGMT - Book value capitalization of the company SGMT
Sagimet Biosciences' foundation is its intellectual property, denvatiplastat, a drug being developed to treat metabolic diseases such as NASH. Its book value represents the capital it uses to conduct clinical trials. The graph tells the story of a biotech company raising capital after positive research results, strengthening its balance sheet.
SGMT - Share of the company's book capitalization SGMT within the market segment - Pharma metabolism
Sagimet Biosciences develops drugs to treat metabolic diseases. The chart shows its share of actual R&D assets. These are its laboratories where research is conducted to create first-in-class drugs to combat diseases such as acne and cancer.
Market segment balance sheet capitalization - Pharma metabolism
Sagimet Biosciences is a biotech company in the R&D stage. Its business is lightweight. The chart below reflects the capital intensity of the entire pharmaceutical sector, which makes its asset-light, science-focused model particularly compelling.
Book value of all companies included in the broad market index - GURU.Markets
Sagimet Biosciences develops therapies for the treatment of metabolic diseases such as non-alcoholic steatohepatitis (NASH). The company's assets provide capital for clinical trials. Its modest stake in BCap_All provides a material resource aimed at solving one of the most common and complex liver diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - SGMT
Sagimet Biosciences is a biotech company. Its high market capitalization is a premium bet on the success of its lead drug for the treatment of metabolic liver disease (NASH), a huge but challenging market to develop.
Market to book capitalization ratio in a market segment - Pharma metabolism
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases. Its valuation is driven by the potential of its lead candidate. This metric represents a significant premium to book value, reflecting investor expectations for success in clinical trials.
Market to book capitalization ratio for the market as a whole
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as acne and cancer. Its valuation is based on the potential of its scientific developments. This chart demonstrates how market value in biotech can be detached from book value, reflecting the hopes for future drugs.
Debts of the company, segment and market as a whole
SGMT - Company debts SGMT
Sagimet Biosciences, a biopharmaceutical company developing drugs to treat metabolic diseases, uses debt to finance its clinical programs. The debt burden reflects the cost of conducting expensive trials targeting diseases like steatohepatitis, which require significant investment.
Market segment debts - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotech company developing drugs for the treatment of metabolic diseases such as fatty liver disease (NASH). Funding in this field is critical for conducting lengthy and expensive trials. This chart shows the company's financial strategy for advancing its development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio SGMT
Sagimet Biosciences is a biotech company focused on treating metabolic diseases such as acne and cancer. The long clinical trials process requires stable funding. This chart reflects the company's reliance on debt, allowing investors to assess the risks associated with raising capital to continue R&D.
Market segment debt to market segment book capitalization - Pharma metabolism
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart shows debt trends in their sector, allowing one to assess how the company finances its expensive clinical trials in one of the most complex and competitive areas of modern medicine.
Debt to book value of all companies in the market
Sagimet Biosciences is a biotech company focused on treating metabolic diseases such as GERD. Being in clinical development, the company likely relies on equity rather than debt. This chart of the overall market debt burden highlights the contrast between the financial model of innovative biotech and traditional, leveraged sectors of the economy.
P/E of the company, segment and market as a whole
P/E - SGMT
Sagimet Biosciences is a biopharmaceutical company developing drugs to treat metabolic diseases such as steatohepatitis (NASH). This chart reflects investor expectations for a potential blockbuster in a huge market. The company's valuation is based not on current revenue, but on clinical trial success.
P/E of the market segment - Pharma metabolism
This industry chart for biotech companies provides key context for Sagimet Biosciences. It reflects overall high valuations based on breakthrough hopes. Comparisons with this chart help understand whether Sagimet's development in metabolic liver disease (MASH) is considered more promising than that of dozens of other biotechs in this competitive field.
P/E of the market as a whole
Sagimet Biosciences develops drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a huge market with no approved drugs. The company's valuation is a bet on success in highly complex clinical trials. This biotech risk appetite chart shows whether investors are willing to tolerate a high probability of failure for the chance of a blockbuster.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company SGMT
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart shows speculative investor expectations. The valuation depends on clinical trial results and the potential to be one of the first companies to have a treatment approved for this common disease.
%20P%2FE%20SGMT&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-SGMT&v=1772624566623 "Chart of the company's future (projected) P/E SGMT")
Future (projected) P/E of the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat metabolic diseases such as non-alcoholic steatohepatitis (NASH). This chart reflects investor expectations for the company's profitability relative to the sector. It allows one to assess the market's perception of its chances of success in one of the most challenging areas of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772624566653 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Sagimet Biosciences is a clinical-stage biotech company developing drugs to treat metabolic diseases such as steatohepatitis (NASH). Given the overall market expectations shown by this chart, Sagimet's business depends on scientific breakthroughs. The success of their clinical trials in a huge and currently unmet medical need is their primary driver.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624566670 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit SGMT
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). This represents a huge market with an unmet need. This chart shows the company's financial position at the clinical trial stage in one of the most pressing areas of medicine.
Profit of companies in the market segment - Pharma metabolism
Sagimet Biosciences is a biotechnology company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart shows the company's profitability in the pharmaceutical sector. For SGMT, this reflects the enormous unmet need to treat obesity-related liver diseases, where no approved drugs currently exist.
Overall market profit
Sagimet Biosciences is a clinical-stage biotechnology company developing drugs for the treatment of metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This represents a huge potential market. The company's success depends on the results of clinical trials. This graph of total corporate profitability is not relevant to its scientific prospects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company SGMT
Sagimet Biosciences is a biotechnology company developing drugs for the treatment of metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), or fatty liver disease. The revenue projections presented here are speculative and depend on the success of its lead candidate in clinical trials in this large but complex market.
%20profit%20of%20the%20company%20SGMT&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-SGMT&v=1772624566778 "Graph of future (projected) profit of the company SGMT")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). The company's revenue forecast for this segment depends on the outcome of clinical trials. This chart reflects analysts' confidence that an effective treatment for this common disease will finally be available.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772624566798 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Sagimet Biosciences is a clinical-stage biotechnology company developing drugs to treat metabolic diseases such as steatohepatitis (NASH). Its success depends on research results. Market revenue projections, as presented here, impact the availability of capital to fund lengthy and expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624566809 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - SGMT
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart shows a speculative valuation. Investors are betting that the company will be able to create the first effective drug for this huge and currently untapped market.
P/S market segment - Pharma metabolism
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). It's a large but complex market. This chart shows the average revenue estimate for the sector, which helps understand investor expectations for Sagimet's clinical trials and potential success.
P/S of the market as a whole
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). The company is in late-stage clinical trials. This chart provides a general market backdrop for assessing investor sentiment on the potentially multi-billion dollar, yet risky, NASH treatment market.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company SGMT
Sagimet Biosciences is a clinical-stage biotechnology company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). This chart shows how the market values the company based on its future revenue potential, reflecting expectations for success in treating common liver diseases.
%20P%2FS%20SGMT&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-SGMT&v=1772624566962 "The graph of the company's future (projected) P/S SGMT")
Future (projected) P/S of the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases such as non-alcoholic steatohepatitis (NASH). This chart reflects investor expectations for its lead drug candidate and the potential to enter the large but complex liver disease market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772624566973 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Sagimet Biosciences is a clinical-stage biotech developing drugs to treat metabolic diseases such as non-alcoholic steatohepatitis (NASH). This market optimism chart is important for SGMT. Funding expensive clinical trials for diseases with a huge market is only possible with a high investor risk appetite.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624567005 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales SGMT
Sagimet Biosciences is a clinical-stage biotechnology company focused on developing drugs for the treatment of metabolic diseases, such as non-alcoholic steatohepatitis (NASH). The company currently has no commercial products. This pipeline will demonstrate its ability to bring in-demand therapies for liver disease to market.
Sales of companies in the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotechnology company developing a new class of drugs for the treatment of metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). Their lead candidate targets a key enzyme in fat metabolism. The company is in the research phase and has not yet generated commercial revenue.
Overall market sales
Sagimet Biosciences is a biopharmaceutical company developing drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a serious liver disease. This revenue chart includes the healthcare sector, where SGMT is working to address a growing lifestyle-related public health issue.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company SGMT
Sagimet Biosciences is a biopharmaceutical company developing drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). This chart reflects analysts' expectations for clinical trial success in this vast but challenging drug development market.
%20sales%20of%20the%20company%20SGMT&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-SGMT&v=1772624567285 "Schedule of future (projected) sales of the company SGMT")
Future (projected) sales of companies in the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biopharmaceutical company developing drugs to treat metabolic diseases such as non-alcoholic steatohepatitis (NASH). This chart shows forecasts for the vast, yet unmet, market for NASH treatment. It reflects expectations for the first approved drugs in this area.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772624567371 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Sagimet Biosciences, a biotech company focused on treating metabolic diseases such as steatohepatitis (NASH), sees this chart as a reflection of healthcare priorities. The economic growth projected here allows healthcare systems and investors to focus more on chronic disease treatment, which is important for funding Sagimet's development.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624567511 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality SGMT
Sagimet Biosciences is a biotech company focused on treating metabolic diseases such as steatohepatitis. Being in the clinical stage, it incurs significant research expenses. This chart doesn't show current profits, but rather the "cost of progress"—the amount of investment the company is making in developing a potential drug.
Market segment marginality - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotechnology company developing drugs for the treatment of metabolic diseases such as non-alcoholic steatohepatitis (NASH). This chart reflects market expectations. Future strong operating income will confirm the success of its developments in an area with a significant unmet need.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company SGMT
Sagimet Biosciences is a clinical-stage biotechnology company focused on developing therapies for metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). This graph shows a small team of scientists and physicians conducting clinical trials of their lead drug. Their work is aimed at solving a pressing healthcare problem.
Share of the company's employees SGMT within the market segment - Pharma metabolism
Sagimet Biosciences is a biopharmaceutical company developing drugs to treat metabolic diseases such as nonalcoholic steatohepatitis (NASH). Being at the forefront of the fight against one of the most common liver diseases, it attracts leading scientists. This chart demonstrates its growing influence in this important therapeutic area through its concentration of scientific talent.
Number of employees in the market segment - Pharma metabolism
Sagimet Biosciences is a biotechnology company developing drugs to treat metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), or fatty liver disease. This chart shows the growing team of scientists working to find a solution to one of the most common and complex lifestyle-related diseases of our time.
Number of employees in the market as a whole
Sagimet Biosciences is a biotech company focused on treating metabolic diseases such as acne and cancer. While their work is highly specialized, the overall economic environment, reflected in this chart, is important. A stable labor market ensures an influx of investment into biotech, allowing Sagimet to fund expensive clinical trials of its innovative drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company SGMT (SGMT)
Sagimet Biosciences is a biopharmaceutical company focused on treating metabolic diseases. This timetable reflects investor expectations. Like many biotech companies in the research stage, their per-employee market cap is very high. The market is pricing in the potential success of their lead drug, which is being developed by a small scientific team.
%20of%20the%20company%20SGMT%20(SGMT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-SGMT-SGMT&v=1772624567945 "Chart of market capitalization per employee (in thousands of dollars) of the company SGMT (SGMT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Sagimet Biosciences is a biopharmaceutical company focused on treating metabolic diseases such as steatohepatitis. Its value is determined by progress in clinical trials. This chart reflects investor expectations for its scientific developments, showing its market valuation per employee compared to other biotech companies.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772624567971 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as non-alcoholic steatohepatitis (NASH). This indicator reflects the potential of its lead candidate and indicates how the market perceives the company's chances of success in treating this very common disease.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624568011 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company SGMT (SGMT)
Sagimet is a clinical-stage biotech company developing drugs to treat metabolic diseases such as MASH (liver disease). This graph shows a negative value. The company is spending investor money on R&D. Its research staff isn't generating revenue, but is working on developing a potential blockbuster.
%20Chart%20SGMT%20(SGMT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-SGMT-SGMT&v=1772624568032 "Company Profit Per Employee (in thousands of dollars) Chart SGMT (SGMT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotech company targeting metabolic diseases, specifically nonalcoholic steatohepatitis (NASH). This chart shows the industry average profit per employee. For Sagimet, which is still in the intensive research and development phase, it serves as a benchmark demonstrating the potential profitability of its drug candidates should they be successful.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772624568044 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Sagimet Biosciences is a clinical-stage biotech company focused on developing drugs for metabolic diseases, primarily NAFLD (NASH). This is one of the most complex and in-demand areas in pharma. This chart shows the R&D investment (negative return) per scientist trying to create the first "fatty liver pill."
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624568054 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee SGMT (SGMT)
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases such as steatohepatitis. This graph illustrates the path from research to potential commercialization. Growth in revenue per employee will be a key indicator of the success of its lead drug candidate in clinical trials and on the market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-SGMT-SGMT&v=1772624568073 "Sales chart per company employee SGMT (SGMT)")
Sales per employee in the market segment - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotech company specializing in the treatment of metabolic diseases such as NAFLD (a liver disease). They have no commercial revenue. This chart reflects their R&D stage: their research staff is focused on research, resulting in zero revenue per employee compared to the industry average.
Sales per employee for the market as a whole
Sagimet Biosciences is a biotech company focused on one of the biggest healthcare challenges—metabolic diseases, specifically NASH (non-alcoholic steatohepatitis). It's an R&D company. This graph will likely show minimal revenue, as their team of scientists is in advanced clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company SGMT (SGMT)
Sagimet (SGMT) is a clinical-stage biotech developing drugs (FASN inhibitors) for the treatment of metabolic diseases, particularly steatohepatitis (NASH). This chart measures bearish bets. The high short interest reflects investor skepticism about the NASH market, which has become a "graveyard" for many drugs, or doubts about the effectiveness of their specific approach.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-SGMT-SGMT&v=1772624568264 "Short Shares Chart for the Company SGMT (SGMT)")
Shares shorted by market segment - Pharma metabolism
Sagimet (SGMT) is a biotech developing FASN inhibitors, specifically for the treatment of nonalcoholic steatohepatitis (NASH). This chart illustrates the general skepticism in the biotech sector. It summarizes bearish bets, reflecting investor concerns about intense competition and risks in liver disease treatments.
Shares shorted by the overall market
Sagimet Biosciences is a clinical-stage biotech developing treatments for metabolic diseases such as NASH. When the market is gripped by fear (high values on this chart), the "risk-off" sentiment makes it extremely difficult for biotechs without revenue to raise the capital needed for research.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator SGMT (SGMT)
Sagimet Biosciences (SGMT) is a biotech company developing drugs to treat metabolic diseases, particularly NASH (fatty liver disease) and acne. This chart measures hype. It shows "overheated" (above 70) due to positive clinical trial data or "oversold" (below 30) due to delays or setbacks, which is typical for biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-SGMT-SGMT&v=1772624568362 "RSI 14 indicator chart for the company's stock SGMT (SGMT)")
RSI 14 Market Segment - Pharma metabolism
Sagimet (SGMT) is a biotech company attacking the liver disease (NASH) from a unique angle: they block an enzyme (FASN) responsible for fat production in the liver. This chart tracks overall sentiment in the Pharma/Metabolism sector. It helps investors understand whether SGMT's move is a reaction to their data or whether the entire industry is overheated by the hype surrounding the NASH breakthrough.
RSI 14 for the overall market
Sagimet (SGMT) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SGMT (SGMT)
Sagimet Biosciences is a biotechnology company focused on developing oral medications (FASN inhibitors) for the treatment of metabolic diseases, primarily NASH (non-alcoholic steatohepatitis). This chart shows the average analyst price target, reflecting their expectations for clinical data.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SGMT-SGMT&v=1772624568433 "A chart showing analyst consensus forecasts for the expected stock price. SGMT (SGMT)")
The difference between the consensus estimate and the actual stock price SGMT (SGMT)
Sagimet Biosciences is a clinical-stage biotech focused on metabolic diseases. Their lead drug candidate (Denifanstat) is a bet on the treatment of fatty liver disease (MASH). This chart reflects analysts' high, yet speculative, expectations for their clinical data in this vast but complex market.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SGMT-SGMT&v=1772624568440 "A chart showing the difference between the consensus forecast and the actual stock price. SGMT (SGMT)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Sagimet (SGMT) is a biotech company trying to solve one of the leading "diseases of civilization"—NASH (fatty liver). It's a huge market where many have failed. This chart shows analysts' overall expectations for the metabolic disease sector. It reflects whether experts believe a breakthrough in NASH treatment is possible.
Analysts' consensus forecast for the overall market share price
Sagimet Biosciences is a biotech company developing drugs to treat metabolic diseases, specifically nonalcoholic steatohepatitis (NASH), a fatty liver disease. This chart shows the company's overall risk appetite. For Sagimet, which is working on a treatment for a very common but complex disease, overall market optimism is important for funding expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index SGMT
Sagimet Biosciences is a biotech company attacking the disease of civilization—Fatty Liver Disease (FLD). Their drug (denifanstat) targets the production of fat in the liver (a FASN inhibitor). This chart is a clear indicator of faith in their science. It reflects their R&D progress and the market's assessment of their chances of success in this challenging, yet multi-billion dollar race for FLD.
AKIMA Market Segment Index - Pharma metabolism
Sagimet Biosciences is a clinical-stage biotech developing drugs for the treatment of metabolic diseases, specifically non-alcoholic steatohepatitis (NASH). This chart shows the average pharma sector index, providing investors with a benchmark for how Sagimet's performance compares to the sector average for companies working on this complex problem.
The AKIM Index for the overall market
Sagimet Biosciences is a biotech company developing fatty acid synthesis inhibitors for the treatment of MASH (liver disease), acne, and cancer. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical case study, within the competitive metabolic space, compares to overall economic trends.
